The most common side effectsnausea, vomiting, constipation, and diarrheatypically occur during the first few weeks at each new dose level and diminish as your body adapts
It should describe what the listing is, what records researchers can review, and what the page does not claim
Candidates who typically benefit most from semaglutide therapy include individuals with obesity (defined medically as a body mass index of 30 or higher) or those who are overweight (with a BMI of 27 or higher) and experiencing weight-related health conditions such as elevated cholesterol, diabetes, or high blood pressure
Semaglutide (Ozempic, Wegovy) works only on GLP-1 receptors, primarily controlling hunger without GIP activation
However, both ROS and antioxidants have dual roles: ROS can induce cancer cell death, and some antioxidants may paradoxically promote tumour growth by reducing high levels of naturally occurring ROS in cancer cells, which would otherwise damage and kill the cells